We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use 51²è¹Ý, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A letter providing guidance on the post-transition conversion process was sent by email on 23 October 2020 to the Community MA holders.
Industry must notify the MHRA if they will not be using these flexibilities
How the MHRA assesses marketing authorisation applications (MAA) for medicines referred under Article 29.
Apply now to join the AI Airlock pilot by the MHRA. Benefit from industry and regulatory expert collaboration, bespoke testing plans, and improved regulatory understanding.
Update about the developing role of biosimilar medicines in the NHS in England and the safe, effective and consistent use of biosimilar medicines.
A series of webinars providing guidance on the Windsor Framework agreement and the supply of medicines in Northern Ireland.
Applying for market authorisation for plasma master files (PMFs) and vaccine antigen master files (VAMFs).
A set of principles for understanding the impact of new variants on antiviral drugs and monoclonal antibodies
MHRA scientific and regulatory advice for COVID-19 vaccine developers
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve 51²è¹Ý, we’d like to know more about your visit today. .